| Modulation of cartilage homeostasis by active domains of cell binding extracellular matrix molecules -> Monitor Keywords |
|
|
 
Modulation of cartilage homeostasis by active domains of cell binding extracellular matrix moleculesRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai, CyclopeptidesModulation of cartilage homeostasis by active domains of cell binding extracellular matrix molecules description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20070225215, Modulation of cartilage homeostasis by active domains of cell binding extracellular matrix molecules. Brief Patent Description - Full Patent Description - Patent Application Claims
FIELD OF THE INVENTION [0001] The invention relates to a method for treatment and/or prophylaxis of a disease associated with tissue changes such as, e.g. an inflammatory joint disease such as, e.g., rheumatoid arthritis, psoriatic arthritis, juvenile chronic arthritis, systemic lupus erythematosus (SLE), infectious arthritis and juvenile idiopathic arthritis, other diseases involving joint structures such as, e.g., osteoarthritis, meniscal damage, gout, diseases affecting structural elements of the musculoskeletal system such as, e.g., tendon damage, ligament damage, and bone disease such as, e.g., osteoporosis, diseases affecting major arteries including atherosclerosis, vasculitis and trauma leading to injury, lung diseases including asthma and Chronic Obstructive Pulmonary Disease (COPD). The invention also relates to novel compounds for use in such a method and compositions, and in a preferred aspect the invention relates to novel peptide compounds with the core peptide sequence WLEAK (SEQ ID No. 1). [0002] In the current context the type of tissue changes of main interest is changes involved with inflammatory mediated cartilage destruction. [0003] In further aspects the invention relates to compounds that interact with a receptor such as, e.g., an integrin receptor and/or a polyanionic structure such as, e.g., heparin/heparan sulfate. BACKGROUND [0004] Destruction of tissues is a feature of diseases affecting many organ types and represents an increasing problem to the population with particular emphasis on the aging. Many of these diseases have an element of chronic inflammation. Examples of such diseases are rheumatoid arthritis, osteoarthritis, osteoporosis, artheriosclerosis, chronic lung diseases, tendinitis, spine problems with lower back pain and intervertebral disc hernia. These diseases encompass by far the largest expenditure among major disease categories for society and suffering for individuals. [0005] Arthritis is a common name for several inflammatory joint diseases. Joint diseases are extremely common in the population. While rheumatoid arthritis sufferers represent some 1%, osteoarthritis is much more common with an incidence of at least some 10%. Major features of the two disease entities are progressive destruction of joint structures as well as inflammation causing pain and disability. [0006] At present, the symptoms of conditions such as rheumatoid arthritis can for some patients be alleviated by medical treatment, e.g. anti-inflammatory agents including corticosteroids, physiotherapy or surgery. More recent use of inhibitors of cytokines, particularly TNF-.alpha. has improved the situation for two-thirds of the patients with severe rheumatoid arthritis. However, many patients do not effectively respond to the above-mentioned treatments or the treatments lead to a number of undesired side-effects (see e.g. Smolen & Steiner, Nature Reviews, Vol. 2, (2003), 473-488) [0007] It is known in the art that chondroadherin (CHAD) conjugated with additional compounds has an effect on tissue changes (WO0137861) and it has also been shown that collagen II in combination with chondroadherin (WO03049669) could be used for treating intervertebral discs. The present invention shows to our surprise that chondroadherin and fragments thereof as pure compounds have a desired effect in removing and/or inhibit parameters related to tissue damaging diseases. [0008] There is a need for new approaches with respect to treatment of diseases associated with tissue changes, especially with a view to the efficiency of the treatment and to reduction of side-effects. [0009] Other objects and advantages will be more fully apparent from the following disclosure and appended claims. SUMMARY OF THE INVENTION [0010] The invention herein is a linear or cyclic peptide and the use of said peptide in medicine and especially in the manufacture of a medicament for the treatment and/or prophylaxis of a disease associated with inflammatory mediated cartilage destruction. The minimal core sequence of the linear or cyclic peptide is WLEAK. BRIEF DESCRIPTION OF THE DRAWINGS [0011] FIG. 1 is a bar-graph showing number of cells adhering to substrates chondroadherin and collagen. [0012] FIG. 2A shows pooling of Sephasil column fractions. FIG. 2B shows blocking of adhesion of K9 cells to chondroaherin by peptide pools (p1-p11). [0013] FIG. 3 shows adhesion of k105 cells to chondroadherin. [0014] FIG. 4 shows a Western Blot of chondroadherin binding to heparin-sepharose. [0015] FIG. 5 shows k105 cell adhesion to chondroadherin and collagen type II in the presence and absence of two cell binding peptides. [0016] FIG. 6 shows adhesion of bovine chondrocytes to chondroadherin in the presence or absence of cell binding peptides. [0017] FIG. 7 shows adhesion of k105 cells to chondroadherin with time in the presence or absence of cell binding peptides. [0018] FIG. 8 shows adhesion of k105 cells to cell binding peptides. [0019] FIG. 9 shows adhesion of k105 cells to chondroadherin with time in the presence of three peptides. [0020] FIG. 10 shows adhesion of k105 cells to chondroadherin and the effect of .beta. integrin antibody and EDTA. Continue reading about Modulation of cartilage homeostasis by active domains of cell binding extracellular matrix molecules... Full patent description for Modulation of cartilage homeostasis by active domains of cell binding extracellular matrix molecules Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Modulation of cartilage homeostasis by active domains of cell binding extracellular matrix molecules patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Modulation of cartilage homeostasis by active domains of cell binding extracellular matrix molecules or other areas of interest. ### Previous Patent Application: Use of osteopontin for the treatment and/or prevention of neurologic diseases Next Patent Application: Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Modulation of cartilage homeostasis by active domains of cell binding extracellular matrix molecules patent info. IP-related news and info Results in 0.26043 seconds Other interesting Feshpatents.com categories: Tyco , Unilever , Warner-lambert , 3m 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
